DLBCL

Dr Reid Merryman | ASH 2017 | What is the role of different immunotherapies in DLBCL?

L:

59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA

Dr Reid Merryman
Dana-Farber/Harvard Cancer Center, Boston, US

Interview topic: What is the role of different immunotherapies in DLBCL (Checkpoint inhibitors and engineered T-cell therapy)?